{"id":182835,"date":"2026-08-04T10:55:42","date_gmt":"2026-08-04T05:25:42","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=182835"},"modified":"2026-08-04T10:55:43","modified_gmt":"2026-08-04T05:25:43","slug":"cipla-usfda-eir-invagen-facility-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-usfda-eir-invagen-facility-2026\/","title":{"rendered":"Cipla USFDA EIR: InvaGen Pharmaceuticals Facility Inspection Closed by US Regulator"},"content":{"rendered":"
<\/div>\n

Cipla USFDA EIR issued for InvaGen Pharmaceuticals’ Hauppauge, New York facility, confirming inspection closure. Stock at Rs 1,460, down 0.61%.<\/em><\/p>\n

The Cipla USFDA EIR was issued to InvaGen Pharmaceuticals, Inc., a wholly-owned subsidiary of Cipla, with the US regulator confirming receipt of the Establishment Inspection Report indicating closure of the inspection for its manufacturing facility in the United States.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

The facility covered by the Cipla USFDA EIR is located in Hauppauge, Long Island, New York, USA. An EIR closure is generally viewed as a positive regulatory outcome, signalling that the USFDA has completed its review of the inspection findings without further open observations requiring resolution, a milestone that typically follows a period of remediation work at the site.<\/p>\n\n\n\n\n\n\n\n\n
Detail<\/th>\nValue<\/th>\n<\/tr>\n<\/thead>\n
Subsidiary involved<\/td>\nInvaGen Pharmaceuticals, Inc.<\/td>\n<\/tr>\n
Facility location<\/td>\nHauppauge, Long Island, New York, USA<\/td>\n<\/tr>\n
Regulatory outcome<\/td>\nEIR issued, inspection closed<\/td>\n<\/tr>\n
Cipla<\/a> stock move<\/td>\nDown 0.61% to Rs 1,460<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n